Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ALMS is 25.20M, and currently, short sellers hold a 16.24% ratio of that float. The average trading volume of ALMS on April 24, 2025 was 683.11K shares.
ALMS) stock’s latest price update
Alumis Inc (NASDAQ: ALMS)’s stock price has dropped by -5.23 in relation to previous closing price of 4.97. Nevertheless, the company has seen a loss of -7.83% in its stock price over the last five trading days. globenewswire.com reported 2025-04-21 that ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis Merger maximizes the potential value for ACELYRIN stockholders and creates a stronger combined company, best-positioned to realize long-term value of multiple late-stage assets ACELYRIN files investor presentation highlighting benefits of proposed merger and comprehensive Board process Special Meeting of Stockholders for both companies to be held May 13, 2025 SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, April 21, 2025 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, and ACELYRIN, INC.
ALMS’s Market Performance
ALMS’s stock has fallen by -7.83% in the past week, with a monthly rise of 24.77% and a quarterly drop of -31.74%. The volatility ratio for the week is 10.22% while the volatility levels for the last 30 days are 25.56% for Alumis Inc The simple moving average for the past 20 days is -28.00% for ALMS’s stock, with a -48.49% simple moving average for the past 200 days.
Analysts’ Opinion of ALMS
Many brokerage firms have already submitted their reports for ALMS stocks, with Oppenheimer repeating the rating for ALMS by listing it as a “Outperform.” The predicted price for ALMS in the upcoming period, according to Oppenheimer is $32 based on the research report published on January 30, 2025 of the current year 2025.
Robert W. Baird, on the other hand, stated in their research note that they expect to see ALMS reach a price target of $25. The rating they have provided for ALMS stocks is “Outperform” according to the report published on October 31st, 2024.
H.C. Wainwright gave a rating of “Buy” to ALMS, setting the target price at $30 in the report published on October 17th of the previous year.
ALMS Trading at -13.27% from the 50-Day Moving Average
After a stumble in the market that brought ALMS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.19% of loss for the given period.
Volatility was left at 25.56%, however, over the last 30 days, the volatility rate increased by 10.22%, as shares surge +17.75% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.28% lower at present.
During the last 5 trading sessions, ALMS fell by -7.83%, which changed the moving average for the period of 200-days by -58.86% in comparison to the 20-day moving average, which settled at $6.54. In addition, Alumis Inc saw -40.08% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALMS starting from Colowick Alan, who purchase 16,104 shares at the price of $6.97 back on Apr 01 ’25. After this action, Colowick Alan now owns 16,104 shares of Alumis Inc, valued at $112,309 using the latest closing price.
Colowick Alan, the Director of Alumis Inc, purchase 2,300 shares at $7.49 during a trade that took place back on Apr 02 ’25, which means that Colowick Alan is holding 18,404 shares at $17,235 based on the most recent closing price.
Stock Fundamentals for ALMS
The total capital return value is set at -1.04. Equity return is now at value -198.66, with -136.66 for asset returns.
Based on Alumis Inc (ALMS), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -8.3.
Currently, EBITDA for the company is -297.6 million with net debt to EBITDA at 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.01.
Conclusion
To put it simply, Alumis Inc (ALMS) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
